Skip to Content
Merck
  • A feedforward circuit shaped by ECT2 and USP7 contributes to breast carcinogenesis.

A feedforward circuit shaped by ECT2 and USP7 contributes to breast carcinogenesis.

Theranostics (2020-09-16)
Qi Zhang, Cheng Cao, Wenchen Gong, Kaiwen Bao, Qian Wang, Yuejiao Wang, Liyuan Bi, Shuai Ma, Jiao Zhao, Ling Liu, Shanshan Tian, Kai Zhang, Jie Yang, Zhi Yao, Nan Song, Lei Shi
ABSTRACT

Rationale: A number of guanine nucleotide exchange factors (GEFs) including epithelial cell transforming factor ECT2 are believed to drive carcinogenesis through activating distinct oncogenic GTPases. Yet, whether GEF-independent activity of ECT2 also plays a role in tumorigenesis remains unclear. Methods: Immunohistochemical (IHC) staining, colony formation and xenograft assays were used to examine the role of ECT2 in breast carcinogenesis. Co-immunoprecipitation, immunofluorescent stainings, in vivo deubiquitination and in vitro deubiquitination experiments were performed to examine the physical and functional interaction between ECT2 and ubiquitin-specific protease USP7. High-throughput RNA sequencing, quantitative reverse transcription-PCR and Western blotting were employed to investigate the biological significance of the interplay between ECT2 and USP7. Results: We report that ECT2 plays a tumor-promoting role in breast cancer, and GEF activity-deficient ECT2 is able to alleviate ECT2 depletion associated growth defects in breast cancer cells. Mechanistically, we demonstrated that ECT2 physically interacts with ubiquitin-specific protease USP7 and functionally facilitates USP7 intermolecular self-association, -deubiquitination and -stabilization in a GEF activity-independent manner. USP7 in turn, deubiquitinates and stabilizes ECT2, resulting in a feedforward regulatory circuit that ultimately sustains the expression of oncogenic protein MDM2. Conclusion: Our study uncovers a GEF-independent role of ECT2 in promoting survival of breast cancer cells, provides a molecular insight for the reciprocal regulation of ECT2 and USP7, and supports the pursuit of ECT2/USP7 as potential targets for breast cancer intervention.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human USP7
Sigma-Aldrich
Blasticidine S hydrochloride
Sigma-Aldrich
3X FLAG® Peptide, lyophilized powder
Sigma-Aldrich
Doxycycline hyclate
Sigma-Aldrich
Monoclonal ANTI-FLAG® M2 antibody produced in mouse, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
Sigma-Aldrich
Puromycin dihydrochloride from Streptomyces alboniger, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
MISSION® esiRNA, targeting human ECT2
Sigma-Aldrich
Anti-β-Actin antibody, Mouse monoclonal, clone AC-15, purified from hybridoma cell culture
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
Neomycin solution, with 10 mg/mL neomycin in 0.9% NaCl, 0.1 μm filtered, BioReagent, suitable for cell culture
Millipore
ANTI-FLAG® M2 Affinity Gel, purified immunoglobulin, buffered aqueous glycerol solution
BRAND® 96-well microplate, U-bottom, round bottom, non-sterile
Sigma-Aldrich
MG-132(R), ≥95% (HPLC)